Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Light-Based sensor could replace invasive heart monitoring

NCT ID NCT06649435

Diagnosis Sponsor: Seerlinq s. r. o. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called Seerlinq HeartCore that uses light sensors (photoplethysmography) to measure heart pressure without needles or catheters. Researchers enrolled 131 adults with heart failure to see if the device could accurately detect elevated filling pressure in the heart. If it works, this could allow doctors to monitor patients remotely and adjust treatments more easily.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this device could allow heart failure patients to be monitored at home without invasive procedures, potentially reducing hospital visits.
What could go wrong
This is a completed validation study with 131 participants, so results are preliminary. The technology may not be accurate enough for all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

131 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of 131 adult participants aged ≥ 18 years with diagnosed HF, enrolled into three cohorts - RHC, ECHO, RPM, fulfilling all the inclusion and none of the exclusion criteria.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females aged ≥ 18 years * Able to understand, and willing to provide written ICF * Stated willingness to comply with all study procedures * Confirmed diagnosis of heart failure according to the 2021 ESC guidelines Exclusion Criteria: * Pregnancy or female participant lactating * Advanced renal failure (glomerular filtration rate \<25 ml/min or need for renal replacement therapy), * Active malignancy requiring chemotherapy or radiotherapy * Complex congenital heart disease * Ventricular assist device support * Pulmonary hypertension classified as WHO group 1 or groups 3-5. * Other possible unforeseen medical conditions that the investigator deems unsafe for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Photoplethysmography Right heart catheterization

Contacts and locations

Locations

  • Seerlinq s.r.o.

    Bratislava, Nové Mesto, 831 01, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.